La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Evogene a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Evogene..

Evogene (NASDAQ:EVGN) Azioni, Catena delle Opzioni

Evogene

Evogene Ltd is a computational biology company targeting to revolutionize product development for life-science based industries, including human health, agriculture, and industrial applications. The company established its technology, the Computational Predictive Biology (CPB) platform. The CPB platform is designed to computationally discover and develop life-science products based on microbes, small molecules, and genetic elements as the core components for such products. It holds several subsidiaries utilizing the CPB platform for the development of human microbiome-based therapeutics, medical cannabis, ag-biologicals, ag-chemicals, seed traits, and ag-solutions for castor oil production. It generates maximum revenue from the Agriculture segment, followed by Industry.

Evogene Ltd

Evogene Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVGN#NASDAQ">EVGN</a>) stock rallied over 20% on Monday following the <a href="https://www.benzinga.com/topic/mergers-and-acquisitions">announcement of an acquisition</a>.
What Happened: The Israel-based company <a href="https://www.benzinga.com/pressreleases/25/04/n44893783/icl-to-acquire-the-activity-of-evogenes-subsidiary-lavie-bio" target="_blank" rel="noreferrer noopener">agreed</a> to sell a majority of Lavie Bio Ltd., its subsidiary, to ICL. 
Terms of the deal remain undisclosed.
ICL will also gain control of Evogene&#8217;s MicroBoost AI for AG platform.
This strategic acquisition strengthens ICL&#8217;s position in the ag-biologicals sector. Lavie Bio will continue its operations within ICL&#8217;s expanded structure. 
Key assets to be transferred to ICL include Lavie Bio&#8217;s core team, technology platform, microbial bank, and commercial products.
See Also: <a href="https://editorial.benzinga.com/wp-admin/post.php?post=879284&amp;action=edit">Gold Rallies To Record, Dollar Drops &#8211; Global Markets Today While US Slept</a>
Why It Matters: The transaction builds on more than two years of collaboration between ICL and Lavie Bio, focused on developing innovative bio-stimulant solutions for agriculture.
&#8220;We believe this transaction unlocks significant value for Evogene&#8217;s shareholders,&#8221; said Ofer Haviv, CEO of Evogene. &#8220;Integrating Lavie Bio into ICL will accelerate progress in the global ag-biologicals market, driving innovation in agriculture.&#8221;
Price Action: EVGN shares are trading higher by 24.74% at $1.21 premarket Monday.
At last check, it was trading higher by almost 20.5%. 
Now Read:
<ul>
<li><a href="https://www.benzinga.com/government/regulations/25/04/44896834/dollar-hits-3-year-lows-us-stocks-tumble-as-trump-threatens-to-fire-powell-contrarians-of-the-world-unite">Dollar Hits 3-Year Lows, US Stocks Tumble As Trump Threatens To Fire Powell: &#8216;Contrarians Of The World, Unite!&#8217;</a></li>
</ul>

News

BASFY

EVGN

THRY

Evogene Stock Soars After ICL Deal To Acquire Lavie Bio, MicroBoost AI

WIIM

Evogene shares are trading higher after the company announced it will sell its Lavie Bio subsidiary to ICL.

Lavie Bio improves agriculture productivity and sustainability through microbiome-based ag-biological products
REHOVOT, Israel, April 21, 2025 /PRNewswire/ -- Evogene&nbsp;Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVGN#NASDAQ">EVGN</a>) (TASE: EVGN) a leading computational biology company focused on revolutionizing life-science-based product discovery and development, today announced the signing of a definitive agreement under which ICL, will acquire the majority of activity of Evogene's subsidiary, Lavie Bio Ltd. As part of the agreement, ICL will also acquire Evogene's MicroBoost AI for AG platform.
The transaction is expected to close during the second quarter of 2025, subject to the fulfillment of customary closing conditions.
 &nbsp;

ICL To Acquire Majority Activity Of Evogene's Subsidiary Lavie Bio; Term Not Disclosed

Biotech

Health Care

General

During Q4 2024 And The Beginning Of 2025, Evogene Established An Expense Reduction Plan, To Better Align With Its Strategic Goals, Leading To A Reduction Of ~30% In Headcount, To Be Completed By The End Of Q1 2025

Evogene (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVGN#NASDAQ">EVGN</a>) reported quarterly earnings of $0.06 per share which beat the analyst consensus estimate of $(0.72) by 108.33 percent. This is a 104.62 percent increase over losses of $(1.30) per share from the same period last year. The company reported quarterly sales of $1.61 million which missed the analyst consensus estimate of $3.63 million by 55.56 percent. This is a 178.72 percent increase over sales of $578.00 thousand the same period last year.

Earnings

Evogene Q4 2024 GAAP EPS $0.06 May Not Be Comparable To $(0.72) Estimate, Sales $1.61M Miss $3.63M Estimate

<h3>Companies Reporting Before The Bell</h3>
• Priority Tech Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTH#NASDAQ">PRTH</a>) is expected to report quarterly earnings at $0.07 per share on revenue of $227.93 million. 
• KVH Industries (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KVHI#NASDAQ">KVHI</a>) is projected to report quarterly loss at $0.07 per share on revenue of $28.12 million. 
• Dingdong (Cayman) (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DDL#NYSE">DDL</a>) is projected to report quarterly earnings at $0.00 per share on revenue of $793.81 million. 
• Seanergy Maritime Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHIP#NASDAQ">SHIP</a>) is likely to report quarterly earnings at $0.43 per share on revenue of $40.15 million. 
• Dynagas LNG Partners (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DLNG#NYSE">DLNG</a>) is estimated to report quarterly earnings at $0.28 per share on revenue of $38.34 million. 
• ALX Oncology Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALXO#NASDAQ">ALXO</a>) is likely to report earnings for its fourth quarter. 
• Ranpak Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PACK#NYSE">PACK</a>) is expected to report quarterly loss at $0.02 per share on revenue of $100.41 million. 
• VerifyMe (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRME#NASDAQ">VRME</a>) is likely to report quarterly loss at $0.04 per share on revenue of $8.21 million. 
• Xeris Biopharma Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XERS#NASDAQ">XERS</a>) is likely to report quarterly loss at $0.05 per share on revenue of $60.00 million. 
• Stevanato Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STVN#NYSE">STVN</a>) is projected to report quarterly earnings at $0.20 per share on revenue of $352.00 million. 
• Phathom Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHAT#NASDAQ">PHAT</a>) is projected to report quarterly loss at $1.07 per share on revenue of $26.04 million. 
• John Wiley &amp; Sons (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WLYB#NYSE">WLYB</a>) is likely to report earnings for its third quarter. 
• John Wiley &amp; Sons (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WLY#NYSE">WLY</a>) is projected to report quarterly earnings at $0.45 per share on revenue of $401.10 million. 
• Turning Point Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TPB#NYSE">TPB</a>) is projected to report quarterly earnings at $0.75 per share on revenue of $102.27 million. 
• Macy's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/M#NYSE">M</a>) is estimated to report quarterly earnings at $1.91 per share on revenue of $7.84 billion. 
• Burlington Stores (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BURL#NYSE">BURL</a>) is likely to report quarterly earnings at $3.76 per share on revenue of $3.29 billion. 
• Kroger (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KR#NYSE">KR</a>) is expected to report quarterly earnings at $1.09 per share on revenue of $34.87 billion. 
• Mind Medicine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNMD#NASDAQ">MNMD</a>) is projected to report earnings for its fourth quarter. 
• JD.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JD#NASDAQ">JD</a>) is estimated to report quarterly earnings at $0.80 per share on revenue of $45.16 billion. 
• Delcath Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DCTH#NASDAQ">DCTH</a>) is estimated to report quarterly loss at $0.02 per share on revenue of $12.42 million. 
• Cracker Barrel Old (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CBRL#NASDAQ">CBRL</a>) is likely to report quarterly earnings at $0.41 per share on revenue of $836.96 million. 
• GMS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GMS#NYSE">GMS</a>) is projected to report quarterly earnings at $1.40 per share on revenue of $1.29 billion. 
• Superior Industries Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SUP#NYSE">SUP</a>) is expected to report quarterly loss at $0.60 per share on revenue of $300.28 million. 
• Evogene (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVGN#NASDAQ">EVGN</a>) is expected to report quarterly loss at $0.73 per share on revenue of $3.62 million. 
• Marex Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRX#NASDAQ">MRX</a>) is expected to report quarterly earnings at $0.61 per share on revenue of $370.82 million. 
• ProFrac Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACDC#NASDAQ">ACDC</a>) is likely to report quarterly loss at $0.23 per share on revenue of $498.50 million. 
• Toro (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TTC#NYSE">TTC</a>) is expected to report quarterly earnings at $0.63 per share on revenue of $1.01 billion. 
• Sunrise Realty Trust (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SUNS#NASDAQ">SUNS</a>) is projected to report earnings for its fourth quarter. 
• Vanguard Extended Duration Treasury ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EDV#NYSE">EDV</a>) is projected to report earnings for its fourth quarter. 
• BrightSpring Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTSG#NASDAQ">BTSG</a>) is likely to report quarterly earnings at $0.20 per share on revenue of $2.95 billion. 
• America's Car-Mart (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRMT#NASDAQ">CRMT</a>) is expected to report quarterly earnings at $0.17 per share on revenue of $273.39 million. 
• BlackSky Technology (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BKSY#NYSE">BKSY</a>) is projected to report quarterly loss at $0.26 per share on revenue of $34.23 million. 
• Distribution Solns Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DSGR#NASDAQ">DSGR</a>) is likely to report quarterly earnings at $0.33 per share on revenue of $463.80 million. 
• Hippo Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIPO#NYSE">HIPO</a>) is projected to report quarterly earnings at $0.07 per share on revenue of $98.75 million. 
• Polestar Automotive (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSNY#NASDAQ">PSNY</a>) is expected to report quarterly loss at $0.15 per share on revenue of $634.04 million. 
• Canadian Natural Res (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNQ#NYSE">CNQ</a>) is likely to report quarterly earnings at $0.95 per share on revenue of $8.90 billion. 
• Real Brokerage (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REAX#NASDAQ">REAX</a>) is likely to report quarterly loss at $0.05 per share on revenue of $282.20 million. 
• Myers Indus (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MYE#NYSE">MYE</a>) is likely to report quarterly earnings at $0.10 per share on revenue of $203.10 million. 
• TORM (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRMD#NASDAQ">TRMD</a>) is expected to report quarterly earnings at $0.74 per share on revenue of $280.86 million. 
• BJ's Wholesale Club (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BJ#NYSE">BJ</a>) is expected to report quarterly earnings at $0.86 per share on revenue of $5.30 billion. 
<h3>Companies Reporting After The Bell</h3>
• Samsara (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IOT#NYSE">IOT</a>) is expected to report quarterly earnings at $0.07 per share on revenue of $335.35 million. 
• Lexicon Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LXRX#NASDAQ">LXRX</a>) is estimated to report quarterly loss at $0.12 per share on revenue of $6.48 million. 
• DXP Enterprises (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXPE#NASDAQ">DXPE</a>) is estimated to report quarterly earnings at $0.86 per share on revenue of $431.00 million. 
• Reliance Global Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RELI#NASDAQ">RELI</a>) is projected to report earnings for its fourth quarter. 
• Cherry Hill Mortgage (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHMI#NYSE">CHMI</a>) is expected to report quarterly earnings at $0.19 per share on revenue of $2.37 million. 
• Research Frontiers (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REFR#NASDAQ">REFR</a>) is expected to report earnings for its fourth quarter. 
• Silvercrest Asset Mgmt Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAMG#NASDAQ">SAMG</a>) is likely to report quarterly earnings at $0.30 per share on revenue of $31.97 million. 
• Xtant Medical Hldgs (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/XTNT#AMEX">XTNT</a>) is projected to report quarterly loss at $0.02 per share on revenue of $31.80 million. 
• Cango (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CANG#NYSE">CANG</a>) is likely to report earnings for its fourth quarter. 
• ModivCare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MODV#NASDAQ">MODV</a>) is projected to report quarterly earnings at $0.69 per share on revenue of $717.27 million. 
• Comstock (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/LODE#AMEX">LODE</a>) is projected to report quarterly loss at $0.20 per share on revenue of $700 thousand. 
• Marchex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCHX#NASDAQ">MCHX</a>) is likely to report quarterly loss at $0.02 per share on revenue of $12.01 million. 
• GEN Restaurant Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GENK#NASDAQ">GENK</a>) is likely to report quarterly loss at $0.03 per share on revenue of $49.77 million. 
• CytomX Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTMX#NASDAQ">CTMX</a>) is estimated to report quarterly loss at $0.13 per share on revenue of $13.53 million. 
• Atea Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVIR#NASDAQ">AVIR</a>) is estimated to report earnings for its fourth quarter. 
• National CineMedia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCMI#NASDAQ">NCMI</a>) is projected to report quarterly earnings at $0.31 per share on revenue of $83.72 million. 
• Fidus Investment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FDUS#NASDAQ">FDUS</a>) is estimated to report quarterly earnings at $0.52 per share on revenue of $36.66 million. 
• Molecular Partners (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MOLN#NASDAQ">MOLN</a>) is estimated to report quarterly loss at $1.61 per share on revenue of $5.00 million. 
• IDT (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IDT#NYSE">IDT</a>) is expected to report earnings for its second quarter. 
• Smith &amp; Wesson Brands (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWBI#NASDAQ">SWBI</a>) is likely to report quarterly earnings at $0.02 per share on revenue of $119.46 million. 
• Arcturus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARCT#NASDAQ">ARCT</a>) is estimated to report quarterly loss at $0.51 per share on revenue of $45.92 million. 
• Serve Robotics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SERV#NASDAQ">SERV</a>) is expected to report quarterly loss at $0.13 per share on revenue of $254 thousand. 
• Clarus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLAR#NASDAQ">CLAR</a>) is expected to report quarterly earnings at $0.09 per share on revenue of $69.03 million. 
• Guidewire Software (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GWRE#NYSE">GWRE</a>) is expected to report quarterly earnings at $0.52 per share on revenue of $285.83 million. 
• Elutia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELUT#NASDAQ">ELUT</a>) is likely to report quarterly loss at $0.25 per share on revenue of $6.40 million. 
• MeridianLink (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MLNK#NYSE">MLNK</a>) is projected to report quarterly earnings at $0.08 per share on revenue of $78.53 million. 
• Asure Software (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASUR#NASDAQ">ASUR</a>) is estimated to report quarterly earnings at $0.17 per share on revenue of $30.82 million. 
• BigBear.ai Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BBAI#NYSE">BBAI</a>) is projected to report quarterly loss at $0.05 per share on revenue of $54.17 million. 
• Traeger (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COOK#NYSE">COOK</a>) is projected to report quarterly earnings at $0.01 per share on revenue of $164.62 million. 
• Domo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DOMO#NASDAQ">DOMO</a>) is projected to report quarterly loss at $0.16 per share on revenue of $78.00 million. 
• AerSale (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASLE#NASDAQ">ASLE</a>) is estimated to report quarterly earnings at $0.08 per share on revenue of $91.78 million. 
• Guild Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GHLD#NYSE">GHLD</a>) is projected to report quarterly earnings at $0.37 per share on revenue of $272.74 million. 
• Hudson Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HDSN#NASDAQ">HDSN</a>) is expected to report quarterly loss at $0.02 per share on revenue of $37.96 million. 
• a.k.a. Brands Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AKA#NYSE">AKA</a>) is projected to report quarterly loss at $0.23 per share on revenue of $154.49 million. 
• American Outdoor Brands (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AOUT#NASDAQ">AOUT</a>) is likely to report quarterly earnings at $0.10 per share on revenue of $56.78 million. 
• Funko (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FNKO#NASDAQ">FNKO</a>) is likely to report quarterly earnings at $0.00 per share on revenue of $285.79 million. 
• Gevo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GEVO#NASDAQ">GEVO</a>) is likely to report quarterly loss at $0.07 per share on revenue of $3.95 million. 
• American Public Education (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APEI#NASDAQ">APEI</a>) is estimated to report quarterly earnings at $0.62 per share on revenue of $161.78 million. 
• El Pollo Loco Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LOCO#NASDAQ">LOCO</a>) is projected to report quarterly earnings at $0.14 per share on revenue of $115.83 million. 
• Noodles (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDLS#NASDAQ">NDLS</a>) is likely to report quarterly loss at $0.14 per share on revenue of $121.36 million. 
• Potbelly (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBPB#NASDAQ">PBPB</a>) is projected to report quarterly earnings at $0.05 per share on revenue of $115.23 million. 
• Loma Negra Cia Industria (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LOMA#NYSE">LOMA</a>) is estimated to report quarterly loss at $0.10 per share on revenue of $221.13 million. 
• Granite Ridge Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GRNT#NYSE">GRNT</a>) is expected to report quarterly earnings at $0.13 per share on revenue of $104.93 million. 
• Invesco Dorsey Wright Industrials Momentum ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRN#NASDAQ">PRN</a>) is likely to report quarterly loss at $0.47 per share on revenue of $5.92 million. 
• Profound Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PROF#NASDAQ">PROF</a>) is expected to report quarterly loss at $0.34 per share on revenue of $5.92 million. 
• Gap (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GAP#NYSE">GAP</a>) is projected to report quarterly earnings at $0.38 per share on revenue of $4.07 billion. 
• Hewlett Packard (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HPE#NYSE">HPE</a>) is projected to report quarterly earnings at $0.50 per share on revenue of $7.82 billion. 
• HASHICORP INC CL A (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCP#NASDAQ">HCP</a>) is projected to report quarterly earnings at $0.08 per share on revenue of $175.71 million. 
• ACCESS Newswire (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ACCS#AMEX">ACCS</a>) is likely to report quarterly earnings at $0.23 per share on revenue of $7.38 million. 
• Information Servs Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/III#NASDAQ">III</a>) is expected to report quarterly earnings at $0.05 per share on revenue of $57.62 million. 
• Full House Resorts (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FLL#NASDAQ">FLL</a>) is likely to report quarterly loss at $0.19 per share on revenue of $75.78 million. 
• Willdan Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WLDN#NASDAQ">WLDN</a>) is expected to report quarterly earnings at $0.57 per share on revenue of $145.00 million. 
• Broadcom (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGO#NASDAQ">AVGO</a>) is expected to report quarterly earnings at $1.47 per share on revenue of $14.62 billion. 
• Ero Copper (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ERO#NYSE">ERO</a>) is estimated to report earnings for its fourth quarter. 
• Velocity Financial (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEL#NYSE">VEL</a>) is estimated to report quarterly earnings at $0.48 per share on revenue of $42.70 million. 
• Cooper Companies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COO#NASDAQ">COO</a>) is expected to report quarterly earnings at $0.92 per share on revenue of $980.87 million. 
• Costco Wholesale (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COST#NASDAQ">COST</a>) is expected to report quarterly earnings at $4.01 per share on revenue of $62.61 billion. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ACCS

ACDC

ALXO

AOUT

APEI

ARCT

ASLE

ASUR

AVGO

AVIR

BBAI

BlackSky Technology Inc. Class A Common Stock

BKSY

BTSG

BURL

CANG

CBRL

CHMI

CLAR

COOK

COST

CRMT

CTMX

DCTH

DLNG

DOMO

DSGR

DXPE

ELUT

FDUS

FNKO

GENK

GEVO

GHLD

GRNT

GWRE

HDSN

HIPO

KVHI

LOCO

LODE

LOMA

LXRX

MCHX

MLNK

MNMD

MODV

MOLN

NCMI

NDLS

PACK

PBPB

PHAT

PowerShares Dynamic Industrials Sector Portfolio

PROF

PRTH

PSNY

REAX

REFR

RELI

SAMG

SERV

SHIP

STVN

SUNS

SWBI

TRMD

VRME

WLDN

WLYB

XERS

XTNT

Earnings Scheduled For March 6, 2025

AgPlenus Announces Discovery Of New Mode Of Action For Fungicides Against Wheat Disease

Evogene (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVGN#NASDAQ">EVGN</a>) reported quarterly losses of $(1.31) per share which missed the analyst consensus estimate of $(0.63) by 107.94 percent. The company reported quarterly sales of $1.80 million which missed the analyst consensus estimate of $2.85 million by 36.98 percent. This is a 52.32 percent decrease over sales of $3.77 million the same period last year.

Evogene Q3 2024 GAAP EPS $(1.31) Misses $(0.63) Estimate, Sales $1.80M Miss $2.85M Estimate

<h3>Companies Reporting Before The Bell</h3>
• Vestis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VSTS#NYSE">VSTS</a>) is likely to report quarterly earnings at $0.13 per share on revenue of $690.99 million. 
• Nano X Imaging (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NNOX#NASDAQ">NNOX</a>) is expected to report quarterly loss at $0.15 per share on revenue of $3.53 million. 
• Warner Music Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WMG#NASDAQ">WMG</a>) is estimated to report quarterly earnings at $0.31 per share on revenue of $1.60 billion. 
• Construction Partners (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROAD#NASDAQ">ROAD</a>) is estimated to report quarterly earnings at $0.57 per share on revenue of $538.05 million. 
• Cerence (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRNC#NASDAQ">CRNC</a>) is projected to report quarterly loss at $0.38 per share on revenue of $47.65 million. 
• BJ's Wholesale Club (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BJ#NYSE">BJ</a>) is projected to report quarterly earnings at $0.93 per share on revenue of $5.11 billion. 
• Ituran Location &amp; Control (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITRN#NASDAQ">ITRN</a>) is projected to report quarterly earnings at $0.66 per share on revenue of $85.44 million. 
• Baozun (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BZUN#NASDAQ">BZUN</a>) is projected to report earnings for its third quarter. 
• Shoe Carnival (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCVL#NASDAQ">SCVL</a>) is likely to report quarterly earnings at $0.65 per share on revenue of $316.23 million. 
• Atkore (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ATKR#NYSE">ATKR</a>) is projected to report quarterly earnings at $2.47 per share on revenue of $748.32 million. 
• iQIYI (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IQ#NASDAQ">IQ</a>) is likely to report quarterly earnings at $0.04 per share on revenue of $1.02 billion. 
• GreenTree Hospitality Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GHG#NYSE">GHG</a>) is likely to report earnings for its third quarter. 
• PDD Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDD#NASDAQ">PDD</a>) is projected to report quarterly earnings at $2.82 per share on revenue of $14.47 billion. 
• Deere (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DE#NYSE">DE</a>) is projected to report quarterly earnings at $3.87 per share on revenue of $9.35 billion. 
• KE Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BEKE#NYSE">BEKE</a>) is expected to report quarterly earnings at $0.21 per share on revenue of $3.23 billion. 
• Baidu (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIDU#NASDAQ">BIDU</a>) is expected to report quarterly earnings at $2.35 per share on revenue of $4.69 billion. 
• Yunji (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YJ#NASDAQ">YJ</a>) is likely to report earnings for its third quarter. 
• Evogene (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVGN#NASDAQ">EVGN</a>) is projected to report quarterly loss at $1.01 per share on revenue of $2.85 million. 
• Lotus Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LOT#NASDAQ">LOT</a>) is expected to report earnings for its third quarter. 
• RealReal (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REAL#NASDAQ">REAL</a>) is projected to report earnings for its fourth quarter. 
<h3>Companies Reporting After The Bell</h3>
• Copart (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPRT#NASDAQ">CPRT</a>) is estimated to report quarterly earnings at $0.37 per share on revenue of $1.10 billion. 
• UGI (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UGI#NYSE">UGI</a>) is likely to report quarterly loss at $0.29 per share on revenue of $1.65 billion. 
• Matthews International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MATW#NASDAQ">MATW</a>) is likely to report quarterly earnings at $0.38 per share on revenue of $440.46 million. 
• Gap (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GAP#NYSE">GAP</a>) is projected to report quarterly earnings at $0.58 per share on revenue of $3.81 billion. 
• Logility Supply Chain (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGTY#NASDAQ">LGTY</a>) is projected to report quarterly earnings at $0.09 per share on revenue of $25.93 million. 
• Elastic (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ESTC#NYSE">ESTC</a>) is estimated to report quarterly earnings at $0.38 per share on revenue of $354.28 million. 
• Ross Stores (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROST#NASDAQ">ROST</a>) is estimated to report quarterly earnings at $1.40 per share on revenue of $5.15 billion. 
• NetApp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTAP#NASDAQ">NTAP</a>) is estimated to report quarterly earnings at $1.78 per share on revenue of $1.64 billion. 
• Intuit (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTU#NASDAQ">INTU</a>) is estimated to report quarterly earnings at $2.36 per share on revenue of $3.14 billion. 
• Geospace Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GEOS#NASDAQ">GEOS</a>) is projected to report earnings for its fourth quarter. 
• Natural Grocers (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NGVC#NYSE">NGVC</a>) is expected to report earnings for its fourth quarter. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ATKR

BEKE

BIDU

BZUN

CPRT

CRNC

ESTC

GEOS

INTU

ITRN

LGTY

MATW

NGVC

NNOX

NTAP

Citigourp Global Markets 2% Protected Notes Linked To The Djia

REAL

ROAD

ROST

SCVL

VSTS

Earnings Scheduled For November 21, 2024

Evogene (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVGN#NASDAQ">EVGN</a>) will release its quarterly earnings report on Thursday, 2024-11-21. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate Evogene to report an earnings per share (EPS) of $-1.01.
The market awaits Evogene's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.
It's important for new investors to understand that guidance can be a significant driver of stock prices.
<h3>Past Earnings Performance</h3>
During the last quarter, the company reported an EPS beat by $0.14, leading to a 9.3% increase in the share price on the subsequent day.
Here's a look at Evogene's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-1.20</td>
<td>-0.9</td>
<td>-1.4</td>
<td>-1.6</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-1.06</td>
<td>-0.8</td>
<td>-1.3</td>
<td>-0.8</td>
</tr>
<tr>
<td>Price Change %</td>
<td>9.0%</td>
<td>14.000000000000002%</td>
<td>-3.0%</td>
<td>1.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1732115069_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of Evogene were trading at $1.725 as of November 19. Over the last 52-week period, shares are down 71.0%. Given that these returns are generally negative, long-term shareholders are likely a little upset going into this earnings release. 
<a href="https://www.benzinga.com/quote/EVGN/earnings">To track all earnings releases for Evogene visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Glimpse of Evogene's Earnings Potential

Evogene Subsidiary Lavie Bio's LAV321 Bio-Fungicide Advances To Pre-Commercial Stage After 70% Efficacy Against Downy Mildew In Grapes

Evogene shares are trading higher after the company announced a collaboration with Google Cloud to pioneer a generative AI foundation model for novel small molecule design.

The collaboration has the power to foster breakthroughs in small molecule innovation for life science-based products
REHOVOT, Israel, Oct. 31, 2024 /PRNewswire/ -- Evogene Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVGN#NASDAQ">EVGN</a>) (TASE: EVGN), a leading computational biology company aiming to revolutionize life-science-based product discovery and development, today announced a collaboration with Google Cloud to develop a cutting-edge foundation model for generative small molecule de novo design, propelling Evogene's ChemPass AI tech-engine to new levels of innovation. ChemPass AI is a computational technology platform that directs and accelerates the discovery and development of novel products based on small molecules. This groundbreaking initiative seeks to advance the discovery and development of novel small molecules for drug development, sustainable crop protection, and other innovative products across a wide range of life-science industries.

GOOG

GOOGL

Evogene Announces Collaboration With Google Cloud To Pioneer Generative AI Foundation Model For Novel Small Molecule Design, Leveraging Evogene's Deep Expertise In Computational Predictive Biology And Google Cloud's Leadership In AI And Machine Learning

Watershed AC ("Watershed", formerly Colors Farm Ltd.), a cutting-edge company in sustainable&nbsp;aquaculture and biotech and Evogene Ltd. ("Evogene") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVGN#NASDAQ">EVGN</a>)(TASE: EVGN), a leading computational biology company aiming to revolutionize life-science-based product discovery and development, together with Ben-Gurion University (BGU), a renowned Israeli academic research institution, announced receiving an approval from IIA for a second year grant to continue developing &nbsp;CRISPR technology for crustaceans, following a successful first year.
&nbsp;
The collaboration aims to provide a sustainable solution to existing limitations in gene editing for non-model organisms with sparse genomic data and protocols, focusing on improving key traits such as growth rate, disease resistance, and environmental adaptation in crustaceans, targeting giant freshwater prawn, white leg shrimp and red swamp crayfish.
The global shrimp market size was USD 40.35 billion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 7.09% during the 2024-2032 period[1]. The global crayfish market is projected to grow at a CAGR of 31.5% between 2024 and 2032[2]. These growing markets increasingly emphasize the need to expand sustainable aquaculture, making the technology developed in the frame of the collaboration exceptionally relevant.
During the first year the partners successfully met the collaboration's planned goals. Evogene leveraged its advanced&nbsp;GeneRator AI&nbsp;tech-engine and provided predictions for optimal guide RNAs (gRNAs), through several novel features: utilization of un-annotated genomes (lacking gene models), consideration of natural DNA variance in gRNAs design, and off-target prediction to increase editing specificity. This allowed Watershed and BGU to successfully produce the first edited giant freshwater prawn&nbsp;(Macrobrachium rosenbergii) with a selected target trait of colored eye, post larvae at advanced life stages, thereby achieving the main milestone in the utilization of CRISPR technology in crustaceans.
In the second year, the collaboration's main target is to industrially scale-up CRISPR technology for giant freshwater prawn&nbsp;and expand the obtained application to the additional crustacean species, white leg shrimp (Litopenaeus vannamei) and red swamp crayfish (Procambarus clarkia). &nbsp;

Watershed and Evogene Receive Grant to Advance CRISPR Tech for Crustaceans, Targeting Sustainable Aquaculture

Evogene shares are trading higher after the company announced its subsidiary received a grant from the Israel Innovation Authority to advance its program to develop a technology for the delivery of Ag-biologicals to agriculture.

. This patented technology, named 'MicroFermentor', is based on an innovative microbe formulation that enables the multiplication of beneficial bacteria directly on the plant, reducing application costs, extending shelf life, and prolonging the bacteria's viability after field application. The grant was awarded following positive initial microbe encapsulation and greenhouse validation experiments and will support the program's next phase of development toward commercialization.

Lavie Bio, A Subsidiary Of Evogene Received A Grant From The Israel Innovation Authority To Advance Its Program To Develop A Technology For The Delivery Of Ag-biologicals To Agriculture

Lake Street analyst Ben Klieve maintains Evogene (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVGN#NASDAQ">EVGN</a>) with a Buy and lowers the price target from $30 to $12.

Price Target

Analyst Ratings

Lake Street Maintains Buy on Evogene, Lowers Price Target to $12

Offerings

Evogene Prices $5.5M Registered Direct Offering Of 1,692,308 Shares And Concurrent Private Placement

Evogene shares are trading lower after the company reported worse-than-expected Q2 EPS results.

Evogene Q2 2024 GAAP EPS $(1.06) May Not Be Comparable To $(0.12) Estimate, Sales $914.000K Beat $800.000K Estimate

Press Releases

"The Future is Bright: Peraso Inc. (NASDAQ: PRSO) Expands Technology for Tactical Applications in High-Demand Industries – More Stocks Inside…"

Evogene Schedules Third Quarter 2024 Financial Results Release

Lavie Bio Announces Commercial Expansion of Yalos® as Seed-Treatment for Soybean, Following Successful Field Trials

Lavie Bio Advances its Bio-Fungicide LAV321, Targeting Downy Mildew, to Pre-Commercial Stage Following Successful 2024 Field Trial Results

Evogene Reports Third Quarter 2024 Financial Results

AgPlenus Announces Discovery of a New Mode of Action for Fungicides Against Wheat Disease

Evogene Schedules Fourth Quarter 2024 Financial Results Release

Evogene Announces the Appointment of Nir Nimrodi as the New Chairperson of the Board, Effective March 5, 2025

Comments

Evogene

Evogene (EVGN) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO